Long-Term Treatment of Osteopetrosis with Recombinant Human Interferon Gamma

Authors:
  • LKL. Lyndon Jr. Key
    L. Lyndon Jr. Key
  • RRRamona Marie Rodriguiz
    Ramona Marie Rodriguiz
  • NWNancy M. Wright
    Nancy M. Wright
  • HHHeather C. Hatcher
    Heather C. Hatcher
  • DEDavid R. Eyre
    David R. Eyre
  • JCJoel K. Cure
    Joel K. Cure
  • PGPaul P. Griffin
    Paul P. Griffin
  • WRWilliam L. Ries
    William L. Ries

Abstract
Congenital osteopetrosis is a rare osteosclerotic bone disease characterized by both a defect in osteoclastic function and reduced generation of superoxide by leukocytes. The disease is frequently fatal during the first decade of life. A six-month trial of therapy with recombinant human interferon gamma-1b in eight patients with osteopetrosis provided evidence of benefit, prompting this study of more prolonged therapy.

This publication has 18 references indexed in Scilit: